

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Giancarlo Tonon et al.

Application No.: National Phase of  
PCT/IT2004/000529

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: MAMMALIAN CELL LINES MODIFIED  
FOR THE PRODUCTION OF  
RECOMBINANT GLYCOPROTEINS

---

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

104975051

Application No.: National Phase of PCT/IT2004/000529 2

Docket No.: 02901/0203976-US0

IA P20 RES'D PCT/IT 0 3 APR 2006

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed documents.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: April 3, 2006

Respectfully submitted,

*Mitchell Bernstein*  
By *Mitchell Bernstein, Reg. No. 46,550 for*

Adda C. Gogoris

Registration No.: 29,714

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

1AP20 Rec'd PGT/PTO J3 APR 2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b> Application Number <b>10/2901/0203976-51</b> Filing Date <b>Not Yet Assigned</b> First Named Inventor <b>Giancarlo Tonon</b> Art Unit <b>N/A</b> Examiner Name <b>Not Yet Assigned</b> Attorney Docket Number <b>02901/0203976-USO</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)					
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BA	EP-0 752 474-A1	01-08-1997	Schauer et al.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Fontana, Ombretta et al.: "Elimination of N-glycolyneuraminic acid residues in recombinant glycoproteins: A gene knock-out approach"; Animal Cell Technology: Products from Cells, Cells as Products; Proceedings of the Esact Meeting, 16th, Lugano, Switzerland, April 25-29, 1999, Meeting Date 1999, pages 245-249, Editors: Bernard, Alain; Publishers: Kluwer Academic Publishers.	
	CB	DATABASE EMBL 'Online! 9 June 1999, "Circetulus griseus mRNA for cnah protein, partial" XP002315186; retrieved from EBI accession no. EM_PRO:CGR242835; Database accession no. CGR242835.	
	CC	CHENU S et al.; "Reduction of CMP-N-acetylneuraminic acid-hydroxylase activity in engineered Chinese hamster ovary cells using an antisense-RNA strategy"; BBA-General Subjects, Elsevier Science Publishers, NL, vol. 1622, no. 2, 23 July 2003, pages 133-144.	
	CD	HOKKE C H et al.; "Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contains traces of N-glycolyneuraminic acid"; FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL., vol. 275, no. 1/2, November 1990, pages 9-14.	
	CE	WEIKERT, S ET AL.; "Engineering Chinese hamster ovary cells to maximise sialic acid content of recombinant glycoproteins"; NATURE BIOTECHNOLOGY, NATURE PUB. CO., NEW YORK, NY, US., vol. 17, no. 11, November 1999, pages 1116-1121.	
	CF	BRAGONZI A ET AL.; "A new Chinese hamster ovary cell line expressing α2, 6-sialyltransferase used as universal host for the production of human-like sialylated recombinant glycoproteins"; BBA-GENERAL SUBJECTS, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 1474, no. 3, 1 May 2000, pages 273-282.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--